CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 6,165	$ 4,790
Operating expenses:
Cost of goods sold	2,590	2,081
Research and development	24,334	21,273
General and administrative	6,891	9,347
Total operating expenses	33,815	32,701
Operating loss	(27,650)	(27,911)
Other income, net	985	162
Net loss	$ (26,665)	$ (27,749)
Net loss per share:
Basic	$ (0.49)	$ (0.52)
Diluted	$ (0.49)	$ (0.52)
Weighted average shares:
Basic	53,872,038	53,507,060
Diluted	53,872,038	53,507,060
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ 571	$ (1,365)
Total comprehensive loss	(26,094)	(29,114)
Collaborative Revenue
Revenue:
Total revenue	2,750
Commercial Supply Revenue
Revenue:
Total revenue	3,191	$ 4,790
Royalty Revenue
Revenue:
Total revenue	125
Clinical Compound Revenue
Revenue:
Total revenue	$ 99